TKT’s Former CEO Settles SEC Fraud Charges For $1.2 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Charges date to 2005 for misleading statements made about Replagal; Transkaryotic Therapies was later acquired by Shire.